Skip to main content
. 2021 May 14;43(3):672–680. doi: 10.1038/s41401-021-00683-8

Fig. 3. The anti-HER2×PD1 BsAb inhibited the proliferation of HER2-overexpressing tumor cells and blocked the PD1/PDL1 interaction in cell-based bioassays.

Fig. 3

a The BsAb inhibited the proliferation of HER2-overexpressing BT474 cancer cells in a dose-dependent manner similar to trastuzumab. b The ability of the BsAb to block PD1/PDL1 signaling was measured and compared to that of the parental anti-PD1 mAb, 609A, using a PD1/PDL1 blockade cell-based assay, in which the expression of luciferases were monitored under the control of nuclear factor of activated T cells (NFAT) response elements in response to blockade of PD1/PDL1 signaling (Promega Cat#J1250). A nonspecific IgG1 was used as the negative control.